Sanofi India Limited and Sanofi Healthcare India Private Limited, collectively referred to as 'Sanofi India,' along with Cipla Limited, have announced an exclusive partnership for the distribution and promotion of Sanofi India's Central Nervous System (CNS) product range in India. 

As part of the partnership, Cipla will take on the responsibility of distributing Sanofi India's six CNS brands, including Frisium®, a notable name in the anti-epileptic medication category. While Sanofi India retains ownership of its CNS product range, handling importation and manufacturing across plants in India and internationally, Cipla will leverage its extensive network and capabilities to broaden the availability of these treatments.

Rodolfo Hrosz, Managing Director of Sanofi India Limited, expressed confidence in the partnership, stating, "Sanofi India's CNS products are leaders in their respective categories. These well-established brands already improve the lives of many patients across urban centres in the country. Cipla's wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India."

Achin Gupta, Chief Executive Officer of One India Business at Cipla Limited, highlighted the significance of collaboration in addressing patient needs, particularly in the complex field of Central Nervous System disorders. He stated, "Enhancing access to high-quality treatments is central to our purpose of 'Caring for Life'. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country."

The partnership reflects Sanofi India's ongoing commitment to advancing its innovative pipeline in India, spanning multiple therapeutic areas such as diabetes, transplants, rare diseases, consumer healthcare, and vaccines.